Management strategies for female patients of reproductive potential with multiple sclerosis

An evidence-based review

Patricia K. Coyle, Jiwon Oh, Melinda Magyari, Celia Oreja-Guevara, Maria Houtchens

Research output: Contribution to journalReview article

Abstract

Multiple sclerosis (MS)is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the disease itself has no impact on pregnancy, many women living with MS still question their ability to have children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize the importance of proper guidance from healthcare professionals, particularly neurologists. Management considerations are also complicated by the growing list of available treatment options. This review will summarize current evidence and expert opinion around the management of female MS patients of reproductive potential, from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS disease activity in the peripartum period.

Original languageEnglish (US)
Pages (from-to)54-63
Number of pages10
JournalMultiple Sclerosis and Related Disorders
Volume32
DOIs
StatePublished - Jul 1 2019
Externally publishedYes

Fingerprint

Multiple Sclerosis
Peripartum Period
Pregnancy
Immune System Diseases
Expert Testimony
Family Planning Services
Pregnancy Outcome
Postpartum Period
Parturition
Guidelines
Delivery of Health Care
Therapeutics

Keywords

  • Disease modifying therapy
  • Family Planning
  • Multiple sclerosis
  • Postpartum
  • Pregnancy

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Management strategies for female patients of reproductive potential with multiple sclerosis : An evidence-based review. / Coyle, Patricia K.; Oh, Jiwon; Magyari, Melinda; Oreja-Guevara, Celia; Houtchens, Maria.

In: Multiple Sclerosis and Related Disorders, Vol. 32, 01.07.2019, p. 54-63.

Research output: Contribution to journalReview article

Coyle, Patricia K. ; Oh, Jiwon ; Magyari, Melinda ; Oreja-Guevara, Celia ; Houtchens, Maria. / Management strategies for female patients of reproductive potential with multiple sclerosis : An evidence-based review. In: Multiple Sclerosis and Related Disorders. 2019 ; Vol. 32. pp. 54-63.
@article{7cb65173e1d5420d8b4d282ab9d64e95,
title = "Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review",
abstract = "Multiple sclerosis (MS)is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the disease itself has no impact on pregnancy, many women living with MS still question their ability to have children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize the importance of proper guidance from healthcare professionals, particularly neurologists. Management considerations are also complicated by the growing list of available treatment options. This review will summarize current evidence and expert opinion around the management of female MS patients of reproductive potential, from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS disease activity in the peripartum period.",
keywords = "Disease modifying therapy, Family Planning, Multiple sclerosis, Postpartum, Pregnancy",
author = "Coyle, {Patricia K.} and Jiwon Oh and Melinda Magyari and Celia Oreja-Guevara and Maria Houtchens",
year = "2019",
month = "7",
day = "1",
doi = "10.1016/j.msard.2019.04.003",
language = "English (US)",
volume = "32",
pages = "54--63",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Management strategies for female patients of reproductive potential with multiple sclerosis

T2 - An evidence-based review

AU - Coyle, Patricia K.

AU - Oh, Jiwon

AU - Magyari, Melinda

AU - Oreja-Guevara, Celia

AU - Houtchens, Maria

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Multiple sclerosis (MS)is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the disease itself has no impact on pregnancy, many women living with MS still question their ability to have children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize the importance of proper guidance from healthcare professionals, particularly neurologists. Management considerations are also complicated by the growing list of available treatment options. This review will summarize current evidence and expert opinion around the management of female MS patients of reproductive potential, from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS disease activity in the peripartum period.

AB - Multiple sclerosis (MS)is an inflammatory, demyelinating, neurodegenerative, immune-mediated disease primarily diagnosed in early adulthood. Multiple sclerosis mostly impacts women of reproductive potential, with pregnancy and birth outcomes being major concerns for many patients. While there is ample evidence that the disease itself has no impact on pregnancy, many women living with MS still question their ability to have children, and the impact of childbearing on their disease in the short and long term. Such questions emphasize the importance of proper guidance from healthcare professionals, particularly neurologists. Management considerations are also complicated by the growing list of available treatment options. This review will summarize current evidence and expert opinion around the management of female MS patients of reproductive potential, from family planning to the postpartum period. Current guidelines on the use of disease-modifying therapies throughout pregnancy will be discussed, as well as other general medical recommendations, to minimize MS disease activity in the peripartum period.

KW - Disease modifying therapy

KW - Family Planning

KW - Multiple sclerosis

KW - Postpartum

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85064699334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064699334&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2019.04.003

DO - 10.1016/j.msard.2019.04.003

M3 - Review article

VL - 32

SP - 54

EP - 63

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -